Company Investors Technology Careers Updates Events Contact Company Our mission is to profoundly improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss Exonate aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DMO), by using mRNA targeted therapies. Video courtesy of British Business Bank’s Business Finance Guide. https://www.youtube.com/embed/rUzMSpyJrlc About Exonate Exonate is a privately held, early stage, biotech, company spun out of the University of Nottingham that is focused on Vascular Endothelial Growth Factor (VEGF). The Company has grown significantly in the last year as it welcomes investment and input from an increasing Global market. It aspires to successfully deliver medicines in areas of unmet need, by targeting diseases through regulation of VEGF isoforms/variants that are both protective and disease promoting. Exonate’s lead program is focused on wet Age-Related Macular Degeneration, (wet AMD), which is the leading cause of vision loss in people aged 60 and older. The Company is founded on scientific excellence with strong links to Prof. David Bates and his lab at Nottingham University specialising in the biology and biochemical pathways of VEGF splice variants. In addition Exonate has formed academic collaborations with the university of New South Wales (Australia) and Professor Jonathan Morris. Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD. Exonate is led by an experienced, international management team that has worked together previously, successfully raising capital for start-ups and early stage companies over many years. Exonate’s management has cross-disciplinary experience in medicine, finance, drug development and the pharmaceutical and biotech industries. CEO Catherine Beech, has over 25 years biotech/pharma experience including 12 years in big pharma leading development programs in cardiovascular, Parkinson’s disease and HIV. Our History Who we are Exonate is a biopharmaceutical company focused on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Alternative mRNA splicing is modulated in disease states resulting in pathological blood vessel formation (angiogenesis) This is a key driver of disease progression in some ophthalmic conditions and cancers. Follow us on Social Media Useful links Career opportunities Technology Investors Contact Copyright © 2021 Exonate Privacy policy Designed and built by Onespacemedia